Health Economics›Diffuse large B-cell lymphoma›Untreated non-randomized or retrospective data

Untreated non-randomized or retrospective data

Diffuse large B-cell lymphoma · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
O-miniCHOP Variant #01	—	R 871 393	21d	—	—	—	—	—
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	—	~9.5 mo	—	—	1
R-BL Variant #02	—	R 29 259	28d	—	—	—	—	—
R-CDOP Variant #01	—	R 25 751	21d	—	—	—	—	—
R-GCVP Variant #01	—	R 19 657	21d	—	—	—	—	—
R-CEOP90 Variant #01	—	R 14 147	21d	—	—	—	—	2
R-CEOP (Etoposide) Variant #01	—	R 13 060	21d	—	—	—	—	—
R-MegaCHOP Variant #01	—	R 12 990	21d	—	—	—	—	—
R-miniCHOP Variant #01	—	R 12 226	21d	—	—	—	—	—
Helicobacter pylori eradication therapy Partial	—	—	—	—	—	—	—	—

10 of 10 regimens shown